Tumor metastasis is a complex phenomenon that is the culmination of effects of numerous cellular factors. We have shown that the Epstein-Barr virus (EBV) oncoprotein, latent membrane protein 1 (LMP1), is capable of inducing a wide range of such factors in cell culture, expression of which is also elevated in the LMP1-expressing tumor, nasopharyngeal carcinoma (NPC), a highly invasive neoplasm. Recently, the membrane crosslinker protein, ezrin, has been implicated in tumor cell metastasis and malignant progression. In this study, we evaluated the possible role of LMP1 and ezrin in the pathophysiology of NPC. We show that C-terminal phosphorylation of ezrin is increased by the expression of LMP1 in nasopharyngeal (NP) cells through a protein kinase C (PKC) pathway. LMP1 enhances the organization of a ternary complex of CD44, ezrin and F-actin, which is a prerequisite for ezrin phosphorylation. In NPC tissues, the expression of phosphoezrin and LMP1 is directly correlated. Silencing of endogenously expressed ezrin suppresses LMP1-induced cell motility and invasiveness. Moreover, the inhibition of ezrin phosphorylation by PKC inhibitor suppresses migration and invasion of NP cells. These data show that the phosphorylation of ezrin and its recruitment to the cell membrane linked to F-actin and CD44 is a process required for LMP1-stimulated cell motility and invasion of NP cells.
Introduction
From a worldwide perspective, nasopharyngeal carcinoma (NPC) is the most important tumor associated with Epstein-Barr virus (EBV) infection. NPC is latently infected with the virus, and monoclonal EBV episomes are present and expressed in the tumor cells in both endemic and sporadic forms of NPC, regardless of geographic origin. The EBV protein, latent membrane protein 1 (LMP1), is detected in most NPC, which classically displays a type II latent gene expression profile that consists of EBNA1, LMP1, LMP2a, LMP2b and Epstein-Barr virus encoded RNAs (EBERs). Among them, LMP1, the principal oncoprotein, is considered to be a key factor in NPC development (Tsao et al., 2002a; Lo et al., 2004) .
Among head-and-neck cancers, NPC is distinguished by its highly metastatic character and poor prognosis (Lo et al., 2004) . LMP1 is known to elicit its oncogenic properties by constitutively activating multiple signaling pathways, such as nuclear factor-kB, c-Jun, AP-1 (activating protein-1), JAK3 (Janus kinase 3)/STAT (signal transducers and activators of transcription), p38MAPK (mitogen-activated protein kinase) and, recently identified, the protein kinase C (PKC) pathway (Yan et al., 2007) . We have shown that LMP1 induces the expression of a series of cell-invasiveness and angiogenic factors and their effects in nasopharyngeal (NP) cells, including matrix metalloproteinase 9 (MMP9) (Yoshizaki et al., 1998) , MMP1 and MMP3 (Kondo et al., 2005) , c-Met and ets-1 (Horikawa et al., 2001) , fibroblast growth factor 2 (Wakisaka et al., 2002) , vascular endothelial factor (Murono et al., 2001) , hypoxia-inducible factor 1a (Wakisaka et al., 2004) , MUC1 , Siah 1 (Kondo et al., 2006) and Twist . Several of these factors are expressed in NPC tissues in association with LMP1, and are thought to be involved in invasion and metastasis of NPC (Yoshizaki et al., 2005) .
The ability of primary tumor cells to migrate is an early contributor to tumor cell metastasis. Cell migration is a highly regulated process that shapes the organization of every tissue in the body (Hopkins et al., 2007) . Recently, it has been reported that ezrin modulates remodeling of actin cytoskeleton and is implicated in tumor cell migration and progression of certain tumors (Fais, 2004; Khanna et al., 2004; Bruce et al., 2007) .
Ezrin is a member of the ezrin/moesin/radixin (ERM) family that acts as a linker between the plasma membrane and the actin cytoskeleton, and generates propulsive forces driving cell migration (Hopkins et al., 2007) . ERM proteins are highly homologous to one another and there is no clear functional difference among them (Martin et al., 2003) . The ERM family exhibits a tissue-specific expression pattern; Ezrin is the most ubiquitous ERM protein in epithelial cells and thought to play an important role in progression of several cancers (Khanna et al., 2004; Auvinen et al., 2007) . Moesin is enriched in endothelial cells and leukocytes, and radixin is abundant in the liver (Doi et al., 1999) . In the cytoplasm, ezrin exists in an autoinhibited conformation through an intramolecular interaction between its N-terminal and C-terminal domains or through the formation of oligomers that include ezrin and other ERM proteins. This interaction masks membrane and F-actin-binding sites. Cellular signals trigger the activation of ezrin, resulting in the unmasking of the functional binding sites (Louvet-Valle´e, 2000; Auvinen et al., 2007) . Several residues of ezrin have recently been found to be phosphorylated and in that state functionally active (Louvet-Valle´e, 2000) . Specifically, the phosphorylation of ezrin on its C-terminal threonine 567 (Thr 567 ) unmasks its binding sites for actin and cell membrane in its conformationally activated form (Fievet et al., 2004) . In this state, ezrin moves to the cell membrane and tethers actin to it, which also affects the architecture and dynamics of the actin cytoskeleton. Basic to these functional effects is the phosphorylation of ezrin, which occurs upon stimulation of cells with hepatocyte growth factor (HGF) or epidermal growth factor (EGF) or androgen, resulting in the modification of cell morphology (Crepaldi et al., 1997; Chuan et al., 2006) .
Central functions of ezrin are the regulation of cell shape, motility, adhesion and signal transduction, all of which are important for tumor development and progression (Fais, 2004) . Here, we analyse phosphorylation and activation of ezrin induced by LMP1 and show that phosphoezrin localizes predominantly in the cell membrane linked to CD44 and that the depletion of ezrin by small-interfering RNA (siRNA) significantly attenuates LMP1-stimulated cell motility and invasion. Also, in NPC tissues, the expressions of phosphoezrin and LMP1 are directly correlated.
Results

LMP1 phosphorylates ezrin at Thr 567 but does not induce its expression
To investigate whether LMP1 affects the induction or the phosphorylation of ezrin, we used a nonmalignant EBV-negative NP cell line, Ad-AH. No effect on the level of ezrin protein was produced by the expression of LMP1. However, the phosphorylation of ezrin detected with phosphoezrin antibody, which recognizes only protein phosphorylated on Thr 567 in the C-terminal region, significantly increased in both transiently and stably transfected cells (Figure 1a) . Although phosphorylated moesin and radixin might be detected, ezrin is the most ubiquitous ERM protein in epithelial cells. We next investigated endogeneous levels of phosphoezrin in a set of type II latently EBV-infected cell lines, KH1 and KH2, which were derived by somatic cell fusion of a latently EBV-infected type III lymphoblastoid KR4 cell line with HeLa cells (Contreras-Brodin et al., 1991) . HeLa cells stimulated with EGF were used as a positive control for phosphorylation of ezrin (Baumgartner et al., 2006) . In both type II cell lines, endogenous phosphoezrin levels were higher than in the parental HeLa cells, which are EBV-negative ( Figure 1b) .
To examine the viral mechanism of phosphorylation, we used mutants of expression plasmids of the principal LMP1 intracellular signaling domains, CTAR1 and CTAR2. LMP1 1-187, which has both CTAR1 and CTAR2 deleted, had no effect on the phosphorylation of ezrin. Both LMP1 1-231, which has CTAR1 only, and LMP1 del 187-351, which has CTAR2 only, induced phosphoezrin, but phosphorylation was weaker than when induced by LMP1-WT (Figure 1c ). These findings indicate that LMP1 can produce an increase in ezrin Thr 567 phosphorylation in NP cells, and that both LMP1 CTAR1 and CTAR2 participate.
LMP1 modulates translocation of ezrin from the cytosol to the plasma membrane C-terminal phosphorylated ezrin is known to be activated and recruited to the plasma membrane (Gautreau et al., 2002) . We investigated the localization of endogenous ezrin phosphorylated by LMP1 using another nonmalignant EBV-negative NP cell line, NP69. In LMP1-expressing NP69 cells, the level of phosphoezrin was increased compared with parental control NP69 cells ( Figure 2a) ; results were similar to those obtained with Ad-AH cells (Figure 1a) . Figure 2b shows that in control NP cells, ezrin is present in the cytosol and also in cell-cell contacts, which means that most of the ezrin exists in an inactive form. However, in LMP1-expressing cells, ezrin was detected in the plasma membrane. Subcellular fractionation verified this shift in ezrin distribution caused by LMP1: ezrin and phosphoezrin were mostly detected in the cytosol fraction, but only in the plasma membrane fraction in LMP1-expressing cells (Figure 2c ). Moreover, immunofluorescence analysis revealed phosphoezrin in the plasma membrane (Figure 2d ). Thus, LMP1 mediates translocation of ezrin from the cytoplasm to the cell membrane, which indicates that phosphorylated ezrin is activated and is positioned to function as a crosslinker protein between adhesion molecules and actin cytoskeleton.
LMP1 modulates phosphorylation of ERM protein, which links to CD44 Phosphorylation of ezrin on Thr 567 is reported to activate and disrupt intramolecular association and changes in ezrin localization; the formation of actinrich structures near the cell membrane is also produced by the phosphorylation of ezrin on Thr 567 (Gautreau et al., 2002; Fievet et al., 2004) . To look for potential binding candidates for ezrin, we evaluated which membrane-anchored cell adhesion molecule binds phosphorylated ezrin. LMP1 is reported to be associated with ICAM-1 and CD44 (Walter et al., 1995; Park and Faller, 2002) . Figure 3a shows that in LMP1-expressing cells, ezrin could be co-precipitated by CD44 antibody. In addition, CD44 could be coprecipitated by ezrin antibody in LMP1-expressing cells ( Figure 3b ) Double-staining with CD44 and ezrin antibodies showed that both proteins were colocalized at the plasma membrane in LMP1-expressing cells ( Figure 3c ). Interaction of ezrin with ICAM-1 was not detected by IP (data not shown). These data suggest that ezrin as modulated by LMP1 is recruited to the cell membrane and forms crosslinks between CD44 and actin cytoskeleton.
Expression of phosphoezrin correlates directly with LMP1-positivity in NPC tissue
On the basis of the results in the cell culture models, we next tested whether phosphoezrin could be detected in LMP-positive NPC tissues (see details in Materials and methods). Immunohistochemical staining revealed phosphoezrin mainly in the plasma membrane and cytoplasm of the tumor cells ( Figure 4a ). LMP1 protein was also located in the membrane and cytoplasm (Figure 4b ). Expression scores for phosphoezrin and LMP1 were closely correlated (r ¼ 0.676; Po0.001) (Figure 4c ). These results support the conclusion that LMP1 induces the C-terminal phosphorylation of ezrin not only in cell culture but also in tumor tissue in vivo.
Ezrin plays a pivotal role in LMP1-stimulated cell morphology, motility and invasiveness The regulation of cell shape, motility and invasiveness by ezrin in its phosphorylated state is well documented (Khanna et al., 2004; Chuan et al., 2006) . We therefore studied the contribution of LMP1-induced phosphoezrin to such properties using siRNA targeting ezrin. LMP1-expressing NP cells characteristically have a Phosphorylated ezrin and LMP1-induced cell migration K Endo et al spindle-like fibroblastic appearance, whereas control cells have a cobblestone-like morphology ( Figure 5a ). The fibroblastic appearance disappears in LMP1-expressing cells transfected with ezrin siRNA. The expression of ezrin protein was barely detectable in these cells (Figure 5b ). Thus, ezrin is involved in control of NP cell shape. Next, we assessed the role of ezrin in LMP1-stimulated cell invasiveness. LMP1 significantly enhanced both cell motility in wound-scratch assays (see Materials and methods) and invasiveness in Matrigel invasion assays. All these LMP1-induced phenotypes were significantly suppressed by ezrin siRNA (Figures  6c and d) . These data suggest that ezrin is a downstream target of LMP1-induced signaling and is essential for a critical step in the metastatic phenotype induced by LMP1.
LMP1 enhances ezrin phosphorylation through PKC not Rho/ROCK pathways Activation of ezrin involves phosphorylation of specific C-terminal Thr residues through several serine/Thr kinases, which are known to phosphorylate ezrin on a C-terminal Thr (Louvet-Valle´e, 2000; Fievet et al., 2004) . Two major pathways have been implicated. One is the small GTP-binding protein Rho and the ROCK (Rho-associated protein kinase) pathway (Tran Quang et al., 2000) . The other is the PKC pathway (Ng et al., 2001; Larsson, 2006) . To examine which might account for the phosphorylation of ezrin in LMP1-expressing cells, we used two inhibitors. Y27632, an inhibitor of ROCK, had no effect on LMP1-stimulated phosphorylation of ezrin, suggesting that ezrin is not a substrate for Rho kinase in NP cells (Figure 6a ). In contrast, pretreatment with Go¨6976, a PKC inhibitor, dramati- Phosphorylated ezrin and LMP1-induced cell migration K Endo et al cally inhibited LMP1 stimulation of Thr 567 phosphorylation (Figure 6b ). LMP1 has been reported to enhance PKC activity, which engages multiple signaling pathways of LMP1 (Yan et al., 2007; Zheng et al., 2007) , and these data point to PKC as an activator of ezrin in LMP1-expressing cells. Phosphorylated ezrin and LMP1-induced cell migration K Endo et al As LMP1 expression in NP cells is known to induce an invasive phenotype (Tsao et al., 2002a) , we next examined, using the two inhibitors, the contribution of phosphorylation state of ezrin to cell motility and invasiveness in wound-scratch and Matrigel invasion assays. In LMP1-expressing NP69 cells, which have B5-fold increased cell motility and invasiveness compared with control cells (Figures 6c and d) , Go¨6976 completely suppressed LMP1-enhanced cell motility and invasiveness, whereas Y27632 had no effect. Thus, LMP1 induces PKCmediated phosphorylation of ezrin, which leads to increases in the effects on cell motility and invasiveness of NP cells. These data stress that ezrin phosphorylation is required for LMP1-stimulated cell motility and invasiveness. 
Phosphorylated ezrin and LMP1-induced cell migration K Endo et al
Discussion
The oncogenic properties of LMP1, the principal EBV oncoprotein, are numerous and continue to be elaborated (Yoshizaki et al., 2005) . The association of the virus and NPC from its inception is virtually universal, and it is likely but not strictly proven that EBV contributes etiologically to this distinctive malignancy. However, in addition, there is strong experimental and pathobiological evidence that LMP1 also affects late stages of oncogenesis through its ability to induce and activate a plethora of cellular factors that promote cell invasion and metastasis, as well as angiogenesis. Initiation of this highly complex process is marked by increases in tumor cell motility. We have shown earlier that LMP1 can induce MMP9 (Yoshizaki et al., 1998) , MMP1, MMP3 (Kondo et al., 2005) , c-Met and ets-1 (Horikawa et al., 2001) , and Twist , all of which produce increases in cell motility and invasiveness.
In this paper, we return to cell motility, but from a quite distinct perspective, namely, through the ERM family proteins typified by ezrin. We show here for the first time that in addition to HGF, EGF and androgen, the viral factor, LMP1, can enhance the formation of a complex of CD44, ezrin and F-actin, which permits phosphorylation of ezrin through PKC and results in increased cell motility and invasiveness, which is neutralized by silencing expression of ezrin (Figure 7) . Moreover, in NPC tissues, there is a direct correlation between the expression of phosphoezrin and LMP1. LMP1 activates multiple signaling cascades, nuclear factor-kB, MAPK, JNK, p38 and JAK/STAT, involved in cell immortalization, cell proliferation and apoptosis (Zheng et al., 2007) . Ezrin is essential for cortical cytoskeleton organization, cell shape, motility, adhesion and intracellular signaling, and has been associated with malignant progression and metastasis in human neoplasias, such as melanoma, lung and endometrial carcinoma, rhabdomyosarcoma and osteosarcoma (Fais, 2004; Khanna et al., 2004; Bruce et al., 2007) . Ezrin is highly expressed in most normal epithelial tissue as well as in many cancers, but normal mesenchymal tissues have relatively low levels of ezrin (Bruce et al., 2007) , suggesting that there are tissue-specific functions for ezrin. Ezrin overexpression in prostate cancer cells is alone not sufficient to promote cell invasiveness (Chuan et al., 2006) . According to these studies, evaluating ezrin Phosphorylated ezrin and LMP1-induced cell migration K Endo et al in the active state is more important in malignant behavior than the expression of total ezrin because of the ubiquitousness of ezrin in cancer as well as in normal epithelial tissues.
Ezrin can exist in both inactive and active forms, and phosphorylation of ezrin regulates its activities (LouvetValle´e, 2000) . Phosphorylation of the conserved C-terminal Thr residue within the actin-binding site of ezrin is the major mechanism for regulating conformational changes and functional activities of ezrin (Fievet et al., 2004) . Several protein kinases are known to phosphorylate ezrin in the C-terminal Thr, including Rho/ROCK and PKC (Tran Quang et al., 2000; Ng et al., 2001; Larsson, 2006) . According to our findings, LMP1-induced PKC is required for the phosphorylation of ezrin and its translocation from the cytosol to the cell membrane. PKC comprises a family of phospholipiddependent serine/Thr kinases that regulates a large number of cellular processes, such as cell spreading and migration. PKC isoforms constitute a family of 10-15 members, and the different isoforms have unique effects in cellular regulation (Larsson, 2006) . Among these isoforms, classical PKCa is known to bind and phosphorylate ezrin in fibrosarcoma cells (Ng et al., 2001) . Overexpression of PKCa in MCF-10A human breast cells enhances cell motility (Sun and Rotenberg, 1999) . A recent study showed that LMP1 could activate the PKCa/PKCb pathway (Yan et al., 2007; Zheng et al., 2007) . Our data show that a selective PKCa, but not a Rho/ROCK, inhibitor Go¨6976, which interacts with the ATP-binding site, decreased ezrin phosphorylation modulated by LMP1. Moreover, inhibition of PKC markedly decreased LMP1-stimulated cell migration and invasion, consistent with earlier reports (Ng et al., 2001; Chuan et al., 2006) . However, in an earlier study, epithelial cells exposed to ROCK inhibitor exhibited increased cell motility and invasiveness (Hopkins et al., 2007) , which was explained by an illusory enhancement of cell spreading, produced by stimulation of cell protrusiveness at the migrating front. Our data indicate that ezrin phosphorylation is required for LMP1-induced cell motility and invasiveness.
Once ezrin is phosphorylated and translocates to the plasma membrane, it interacts with a number of cell-surface adhesion molecules, including ICAM-1, ICAM-2, ICAM-3, CD43 and CD44 through its N terminus and links to actin through its C terminus (Martin et al., 2003) . Our observations reveal that ezrin in its active state as modulated by LMP1 links to CD44, the major cell-surface hyaluronan receptor expressed in diverse cell types. Cellular functions that affect the ability of tumor cells to migrate within tissues, transmigrate through vessels and adhere to adjacent and distant organs are contributors to metastasis early in the process. CD44 itself can affect cell migration and metastasis (Martin et al., 2003) . Furthermore, PKC regulates the interaction between CD44 and ezrin, as this complex regulates cell migration (Ng et al., 2001; Orian-Rousseau et al., 2002) . PKC activation leads to the dephosphorylation of Ser325 and at the same time phosphorylation of Ser291 in CD44 (Legg et al., 2002) . Thus, PKC activated by LMP1 may regulate cellular motility by controlling phosphorylation of both ezrin and CD44. Moreover, the ezrin/CD44 complex is known to organize kinase signaling cascades, such as PI3k/AKT (Martin et al., 2003) . We have shown earlier that c-met induced by LMP1 is associated with cell motility in NPC (Horikawa et al., 2001) . As c-met can form a multimeric complex with HGF, which induces phosphorylation of ezrin, we hypothesize that there may be signaling crosstalk between ezrin and c-met induced by LMP1.
We provide here novel data showing that downregulation of ezrin in LMP1-stimulated NP cells results 
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Figure 7 Scheme for proposed mechanism for LMP1-induced phosphorylation of ezrin. LMP1 enhances phosphorylation of ezrin in its C-terminal region through PKC pathway. Phosphorylated ezrin translocates from the cytosol to the plasma membrane and is linked to CD44 and actin cytoskeleton. Phosphorylated ezrin contributes to LMP1-induced changes in cell phenotype, cell motility and invasiveness in NPC. NPC, nasopharyngeal carcinoma; LMP1, latent membrane protein 1; PKC, protein kinase C.
Phosphorylated ezrin and LMP1-induced cell migration K Endo et al in decreased cell motility and invasiveness. In other studies, Ezrin has been implicated in cytoskeletonmediated cell motility through the regulation of cell shape. Recent study shows that silencing of ezrin induces increased E-cadherin expression, which is central to the process of epithelial cell-cell adhesion (Hiscox and Jiang, 1999) . The use of ezrin siRNA or dominant-negative ezrin has revealed that this protein is a key factor in the development of metastasis in some cancers (Khanna et al., 2004; Chuan et al., 2006) . Our findings that silencing of the expression of ezrin inhibits LMP1-induced cell motility and invasion, and that the detection of phosphoezrin correlates directly with LMP1-positivity in NPC suggest perhaps a unique role for ezrin in NPC oncogenesis. We provide here the first evidence that control of phosphorylation and relocation of ezrin by LMP1 regulates cell migration and invasiveness. Understanding of ezrin function and its binding partners in NPC could potentially provide much needed new targets for therapeutic agents that intercept metastasis of this highly invasive malignancy.
Materials and methods
Cell lines and drug treatment
Ad-AH cells, an EBV-negative human NP cell line, were kindly provided by Dr Erik K Flemington (Tulane University, New Orleans, LA, USA) (Takimoto et al., 1988) and maintained in DMEM (Dulbecco's modified Eagle's medium). NP69 and NP69LMP1, human immortalized NP epithelial cells, generous gifts of Dr Sai Wai Tsao (University of Hong Kong, Hong Kong, China), were maintained in keratinocyteserum free medium (SFM) (Tsao et al., 2002b) . KH-1 and KH-2 are EBV-positive type II cell lines derived by the fusion of KR4 (an EBV-positive type III lymphoblastoid cell line) and HeLa cells (human cervical carcinoma), kind gifts of Dr Maria Masucci (Karolinska Institute, Stockholm, Sweden) (Crepaldi et al., 1997) .
EGF was purchased from Sigma (St Louis, MO, USA). Cells incubated with EGF (25 nM) for 1 h. Inhibitors of Rho kinase, Y-27632, PKCa Go¨6976, were from Calbiochem (San Diego, CA, USA). To evaluate the role of Rho kinase or PKC, cells were pretreated with either vehicle Y-27632 (20 mM) or Go¨6976 (1 mM) for 30 min.
Plasmids and antibodies pcDNA3-based LMP1 plasmid (Raab-Traub et al., 1987) and flag-tagged LMP1 mutants (LMP1 1-231, LMP1 del 187-351 and LMP1 1-187) and LMP1-WT have been described (Miller et al., 1997) .
Rabbit monoclonal ezrin antibody and rabbit polyclonal phosphoezrin antibody (Thr567) were purchased from Cell Signaling (Beverly, MA, USA). Mouse CD44 antibody was from Sigma. Mouse LMP1 antibody was from DAKO (Glostrup, Denmark). Horseradish peroxidase-conjugated mouse or rabbit secondary antibody was from Amersham (Little Chalfont, UK).
Ezrin shRNA
For an ezrin shRNA-expressing cell line, retroviruses that encode ezrin shRNA were constructed by ligating ezrin oligonucleotide (GGCUUUCCUUGGAGUGAAA) into a pSuper-retro vector (Oligoengine) (Zhang et al., 2006) . Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used for transfection of NP69 cells, and the transfected cells were selected with puromycin (Stewart et al., 2003) . A negative control cell line was generated by infecting cells with pSuper-puro construct targeting GFP (GCTACGTCCAGGAGGGCAC).
Western blot analysis
Extracts of cellular proteins were prepared as described qearlier (Wakisaka et al., 2002) . Cell lysates were electrophoresed and transferred to the nitrocellulose membrane. Protein concentration was determined by the Bradfold assay (Bio-Rad, Hercules, CA, USA). The membranes were blocked with nonfat dry milk in tris buffer saline (TBS) and probed with primary antibody overnight, followed by a corresponding secondary antibody. Antibody-bound proteins were visualized by the SuperSignal chemiluminescence system (Pierce, Rockford, IL, USA).
Immunoprecipitation
Whole-cell lysates were precleared with A/G PLUS-Agarose beads and incubated with CD44 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or ezrin antibody and then incubated with beads overnight. After intensive washing and centrifugation, immune complexes were separated by SDS-PAGE (polyacrylamide gel electrophoresis) and probed with primary antibody by western blotting.
Immunofluorescence staining Cells cultured on glass coverslips were fixed with 4% paraformaldehyde, washed with PBS (phosphate-buffered saline), permeabilized with 0.5% Triton X-100/PBS and blocked with 0.5% normal donkey serum. Cells were then incubated with primary antibodies to ezrin, phosphoezrin and CD44 overnight, and were the same as used for western blotting.
Subcellular fractionation
Cellular fractions were obtained with a Qproteome Cell Compartment kit (Qiagen, Valencia, CA, USA). Cytosolic and membrane proteins were obtained with specific extraction buffer according to the manufacturer's instructions.
Immunohistochemical analysis of NPC tissues
Primary NPC paraffin-embedded specimens from Kanazawa University Hospital (Ishikawa, Japan) Fukui Saiseikai Hospital (Fukui, Japan), Toyama City Hospital (Toyama, Japan) and Kurobe City Hospital (Toyama, Japan) were used for detection of LMP1 and phosphoezrin. Immunohistochemistry was performed as described before (Horikawa et al., 2001) . Primary antibodies for LMP1 and phosphoezrin were the same as for western blotting. Stained samples of phosphoezrin and LMP1 were evaluated as follows: under light microscopy, two areas that showed high density of stained cells were selected in a Â 40 field, then the number of stained cells from 200 cells was carefully counted in the two areas in a Â 200 field without any clinicopathological knowledge of the patients. The percentage of positive cells obtained as an average of two counts was used as the expression score for both proteins.
Invasiveness and cell wound-migration assays Matrigel was purchased from BD Bioscience (Sparks, MD, USA) and stored at À20 1C. After dilution in serum-free medium, 50 ml of Matrigel suspension were inoculated onto the upper chamber. Matrigel invasiveness assays were carried out according to the manufacturer's instructions. After 72 h, cells adherent to the lower surface of filters were fixed, stained and scores calculated from counts of cells invading through the Matrigel-coated membrane. Cell wound-migration assay was carried out as described earlier (Horikawa et al., 2001) . Briefly, confluent cell monolayers were scratched with a micropipette tip, and spontaneous cell migration was monitored for 24 h. The distance to wound closure was measured in five independent sites per group. Migration was assessed by measuring distances between wound edges.
Statistical analysis
Pearson's correlation coefficient was used to analyze correlations between the expression of LMP1 and phosphoezrin in NPC specimens. The differences in wound migration and invasiveness indices between NP69 cell clones were analyzed by the paired t-test. Error bars indicate s.d. of the mean, and significance was defined at the level of Po0.05. All experiments were repeated at least three times.
